Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Abstract: The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.

Abstract: A reservoir for a nebulizer includes: a tank or bag containing multiple doses of a fluid to be nebulized, and an indicator device for counting or indicating a number of uses performed or still possible with the reservoir, where at least one of: the reservoir includes a connector for fluidically connecting the tank or bag with the nebulizer, the indicator device is actuated by moving the connector relative to the tank or bag, and the reservoir includes or forms an eccentrical linear guidance for a driving part for driving the indicator device.

Abstract: The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.

Abstract: The compound of formula I: compositions thereof, processes for their preparation, and their uses as pesticides.

Abstract: A computer-implemented method and system for tracking near-field communication (NFC)-enabled animals with a portable computing device (PCD) (i.e. mobile phone) may include providing an NFC-tag comprising memory in which the memory contains a unique identifier. The NFC-tag may be coupled to an animal and then the NFC-tag may be scanned with the PCD. A tag identification server may determine if data from the NFC-tag exists in a database and then transmits an animal production facility identifier and one or more animal records associated with data from the NFC-tag from the tag identification server if the data from the NFC-tag exists in the database. Access to a secure memory area on the portable computing device containing a complete set of animal records for an entire animal facility may be granted if the software identifier matches the animal production facility identifier received from the tag identification server.

Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.

Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.

Abstract: The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for the manufacture of compounds according to the invention.

Abstract: A nebulizer for nebulizing a fluid is proposed. The nebulizer includes an indicator device with a rotatable indicator element for counting or indicating a number of actuations performed or still possible with the nebulizer and a rotatable shaft which rotatably drives the indicator element. The indicator device is non-detachably attached to the shaft and/or to an inner part of the nebulizer. The nebulizer may further include a positioning device that keeps the shaft in a defined rotational position and/or blocks the shaft from rotating backwards.

Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.

Abstract: The present invention relates to anti-interleukin-36 receptor (anti-IL-36R1) antibody formulations for administration to a subject.

Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.

Abstract: Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.

Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

Abstract: A cleaning method for sectional cleaning of a filter having several filter sections, the filter sections being cleaned within a cleaning cycle in cleaning processes separated in time from one another, the cleaning method having at least two cleaning cycles and both a time interval between the cleaning processes within the respective cleaning cycle and also a time interval between the end of one of the cleaning cycles and the start of a following one of the cleaning cycles being changed. Moreover, a connecting device for connecting a filter to a cleaning device having a side wall, which borders an internal cross section, which increases along a longitudinal axis of the connecting device and has lateral openings with assigned major axes and a method of connecting the connecting device to a filter device.

Abstract: The present disclosure provides a method for the surface modification of microstructured components having a polar surface, in particular for high-pressure applications. According to the method, a microstructured component is contacted, in particular treated, with a modification reagent, wherein the surface properties of the component are modified by chemical and/or physical interaction of the component surface and of the modification reagent.

Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.